<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1339">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04719182</url>
  </required_header>
  <id_info>
    <org_study_id>PRoAcT-COVID</org_study_id>
    <nct_id>NCT04719182</nct_id>
  </id_info>
  <brief_title>Practice of Adjunctive Treatments in Intensive Care Unit Patients With COVID-19</brief_title>
  <acronym>PRoAcT-COVID</acronym>
  <official_title>Practice of Adjunctive Treatments in Intensive Care Unit Patients With Coronavirus Disease 2019 (PRoAcT-COVID) - an Observational Study in the Netherlands</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rationale Many patients with coronavirus disease (COVID-19) need hospital admission for&#xD;
      oxygen supplementation. A substantial number of patients need intensive care unit (ICU)&#xD;
      admission for escalation of care. ICU doctors and nurses are struggling to provide the best&#xD;
      care for patients with COVID-19. Practice of adjunctive and supportive treatments remains&#xD;
      uncertain.&#xD;
&#xD;
      Objective To determine and compare practice of adjunctive and supportive treatments for&#xD;
      COVID-19 in the Netherlands, and to determine their independent associations with outcome.&#xD;
&#xD;
      Hypotheses Practice of adjunctive and supportive treatments for COVID-19 varies&#xD;
      substantially. Adjunctive and supportive treatments have an independent association with&#xD;
      outcome in ICU patients with COVID-19.&#xD;
&#xD;
      Study design National, multicenter, retrospective observational study. Study population&#xD;
      Intensive care unit (ICU) patients with COVID-19.&#xD;
&#xD;
      Methods In this study we will collect data on diverse treatments during the first 28 days in&#xD;
      ICU, including (a) the types of oxygen support and awake prone positioning; (b) the types of&#xD;
      ventilatory support, (c) rescue therapies for refractory hypoxemia during invasive&#xD;
      ventilation (prone positioning, ventilator adjustments, continuous muscle paralysis, and&#xD;
      extracorporeal membrane oxygenation); (d) adjunctive treatments, including thromboprophylaxis&#xD;
      and anticoagulation, antiviral and immunomodulating therapies, and (e) experimental&#xD;
      supportive treatments. Outcomes include duration of each adjunctive treatment, duration of&#xD;
      ventilation, incidence of tracheostomy, duration of stay in ICU and mortality until day 90.&#xD;
&#xD;
      Study endpoints A combination of adjunctive treatments, including types of oxygen support,&#xD;
      ventilatory support and rescue therapies for refractory hypoxemia during invasive ventilation&#xD;
      (primary), other adjunctive and supportive treatments, tracheostomy rate; duration of&#xD;
      ventilation and ventilator-free days and alive at day 28 (VFD-28), duration of ICU and&#xD;
      hospital stay, and ICU, hospital and 90-day mortality.&#xD;
&#xD;
      Nature and extent of the burden and risks associated with participation, benefit and group&#xD;
      relatedness Retrospective collection of data regarding adjunctive treatments, and clinical&#xD;
      endpoints is without risk for ICU patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 1, 2020</start_date>
  <completion_date type="Anticipated">July 1, 2021</completion_date>
  <primary_completion_date type="Actual">January 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Mortality</measure>
    <time_frame>90 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>ICU, hospital and 90-day mortality</measure>
    <time_frame>90 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Ventilator-free days and alive at day 28</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>ICU length of stay</measure>
    <time_frame>90 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Hospital length of stay</measure>
    <time_frame>90 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proven deep vein thrombosis (DVT)</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of gastrointestinal bleeding</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of acute kidney injury (AKI)</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of tracheostomy</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of renal replacement therapy (RRT)</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proven pulmonary embolism (PE)</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Covid19</condition>
  <condition>Pneumonia</condition>
  <condition>Thrombosis</condition>
  <condition>Thromboembolism</condition>
  <condition>Anticoagulants; Increased</condition>
  <condition>ARDS, Human</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Adjunctive therapies</intervention_name>
    <description>Determine and compare practice of adjunctive and supportive treatments for COVID-19</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with severe coronavirus disease 2019 (COVID-19) admitted to intensive care units&#xD;
        (ICUs) in the Netherlands between September 2020 and January 2021 (i.e. during the second&#xD;
        surge of COVID-19 patients).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  COVID-19, confirmed with PCR; and&#xD;
&#xD;
          -  Admission to one of the participating ICUs, or an emergency location that serves as an&#xD;
             ICU during the pandemic.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt; 18 years&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Amsterdam UMC location AMC</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 18, 2021</study_first_submitted>
  <study_first_submitted_qc>January 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 22, 2021</study_first_posted>
  <last_update_submitted>January 20, 2021</last_update_submitted>
  <last_update_submitted_qc>January 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</investigator_affiliation>
    <investigator_full_name>Prof. Dr. Marcus J. Schultz</investigator_full_name>
    <investigator_title>Prof.</investigator_title>
  </responsible_party>
  <keyword>ARDS</keyword>
  <keyword>COVID-19</keyword>
  <keyword>Lungembolism</keyword>
  <keyword>DVT</keyword>
  <keyword>PPI</keyword>
  <keyword>Adjunctive therapies</keyword>
  <keyword>Mechanical ventilation</keyword>
  <keyword>Prone positioning</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Thromboembolism</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

